E2511 News - LARVOL Sigma

|||||||||| E2511 / Eisai
Non-clinical evidence for modulating synaptic CSF biomarkers by E2511, a novel small molecule TrkA biased positive allosteric modulator (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_1410;
The convergence of clinical global proteomics data and non-clinical data have identified PD biomarkers for E2511 consistent with the proposed mechanism of action. Results are supportive of continued development of a E2511-specific biomarker panel and suggestive of pathway activation in healthy volunteers.

||||||||||  E2511 / Eisai
Trial completion:  A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants (clinicaltrials.gov) -  Sep 9, 2022
P1, N=47, Completed,  Sponsor: Eisai Inc.
Results are supportive of continued development of a E2511-specific biomarker panel and suggestive of pathway activation in healthy volunteers. Recruiting --> Completed

|||||||||| E2511 / Eisai
E2511, A NOVEL SMALL COMPOUND TRKA BIASED POSITIVE ALLOSTERIC MODULATOR, REINNERVATES CHOLINERGIC NEURON VIA ENHANCEMENT OF SPECIFIC TROPHIC SIGNALING OF TRKA IN NON-CLINICAL STUDIES () - Mar 9, 2022 - Abstract #ADPD2022ADPD_1304;
Recruiting --> Completed E2511 enhances cholinergic function by increasing TrkA signaling as biased positive allosteric modulator, and E2511 functionally reinnervates cholinergic neuronal network in Tau tg mice.

||||||||||  E2511 / Eisai
Enrollment open:  A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants (clinicaltrials.gov) -  Dec 10, 2021
P1, N=55, Recruiting,  Sponsor: Eisai Inc.
E2511 enhances cholinergic function by increasing TrkA signaling as biased positive allosteric modulator, and E2511 functionally reinnervates cholinergic neuronal network in Tau tg mice. Not yet recruiting --> Recruiting

||||||||||  E2511 / Eisai
New P1 trial:  A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants (clinicaltrials.gov) -  Dec 6, 2021
P1, N=55, Not yet recruiting,  Sponsor: Eisai Inc.

|||||||||| E2511 / Eisai
[VIRTUAL] E2511, a novel small compound TrkA allosteric modulator, induces a specific trophic signaling via direct binding to TrkA, and can reverse the loss of choline acetyltransferase (ChAT) positive neurons in transgenic models of AD () - Aug 2, 2021 - Abstract #AAIC2021AAIC_2911;
Not yet recruiting --> Recruiting E2511 enhances specific trophic signaling by altering TrkA signaling as specific allosteric modulator via direct binding to TrkA, and E2511 shows the reinnervative effect on cholinergic neurons through activation of TrkA signaling without induction of NGF-like adverse effect.

||||||||||  E2511 / Eisai
Trial completion:  A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants (clinicaltrials.gov) -  Jul 12, 2021
P1, N=45, Completed,  Sponsor: Eisai Inc.
E2511 enhances specific trophic signaling by altering TrkA signaling as specific allosteric modulator via direct binding to TrkA, and E2511 shows the reinnervative effect on cholinergic neurons through activation of TrkA signaling without induction of NGF-like adverse effect. Recruiting --> Completed

||||||||||  E2511 / Eisai
Enrollment open:  A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants (clinicaltrials.gov) -  Jan 22, 2021
P1, N=56, Recruiting,  Sponsor: Eisai Inc.
CLINICALTRIALS. Not yet recruiting --> Recruiting

||||||||||  E2511 / Eisai
New P1 trial:  A Study to Assess the Safety and Tolerability of E2511 in Healthy Participants (clinicaltrials.gov) -  Sep 13, 2020
P1, N=56, Not yet recruiting,  Sponsor: Eisai Inc.



	Diseases Companies Products Productz Mechanisms of Action Sites